VARDENAFIL HYDROCHLORIDE - Generic Drug Details

What are the generic sources for vardenafil hydrochloride and what is the scope of patent protection?

Vardenafil hydrochloride is the generic ingredient in three branded drugs marketed by Bayer Hlthcare, Alembic, Macleods Pharms Ltd, Crossmedika Sa, Stevens J, Teva Pharms, and Zydus Pharms, and is included in ten NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Vardenafil hydrochloride has one hundred and seven patent family members in forty-three countries.

There are six drug master file entries for vardenafil hydrochloride. Eleven suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for VARDENAFIL HYDROCHLORIDE

International Patents:	107
US Patents:	2
Tradenames:	3
Applicants:	7
NDAs:	10
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	85
Patent Applications:	112
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VARDENAFIL HYDROCHLORIDE
What excipients (inactive ingredients) are in VARDENAFIL HYDROCHLORIDE?	VARDENAFIL HYDROCHLORIDE excipients list
DailyMed Link:	VARDENAFIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VARDENAFIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	PHASE3
Tanta University	PHASE3
Damascus University	PHASE1

See all VARDENAFIL HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for VARDENAFIL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		10MG	TABLET, ORALLY DISINTEGRATING;ORAL
		10MG	TABLET, ORALLY DISINTEGRATING;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for VARDENAFIL HYDROCHLORIDE

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for VARDENAFIL HYDROCHLORIDE

G04BE	Drugs used in erectile dysfunction
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for VARDENAFIL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STAXYN	Orally Disintegrating Tablets	vardenafil hydrochloride	10 mg	200179	1	2011-12-22
LEVITRA	Tablets	vardenafil hydrochloride	2.5 mg	021400	1	2009-09-04
LEVITRA	Tablets	vardenafil hydrochloride	5 mg and 10 mg	021400	1	2009-07-10
LEVITRA	Tablets	vardenafil hydrochloride	20 mg	021400	1	2009-03-05

US Patents and Regulatory Information for VARDENAFIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stevens J	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	210738-002	Oct 31, 2018		DISCN	No	No
Macleods Pharms Ltd	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	204632-002	Oct 22, 2019	AB	RX	No	No
Alembic	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	214031-001	Aug 4, 2020	AB	RX	No	No
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010		DISCN	Yes	No	8,613,950		Y
Zydus Pharms	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	208960-001	Oct 31, 2018	AB	RX	No	No

Expired US Patents for VARDENAFIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-004	Aug 19, 2003	6,362,178
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010	6,362,178
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-002	Aug 19, 2003	7,696,206
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-004	Aug 19, 2003	7,696,206
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-001	Aug 19, 2003	6,362,178

International Patents for VARDENAFIL HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
South Korea	20130137723	MEDICAMENTS CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE
Ecuador	SP055541	MEDICAMENTOS QUE CONTIENEN CLORHIDRATO DE VARDENAFILO TRIHIDRATO
Norway	20074848
Portugal	2272505
Morocco	29376	FORMES PHARMACEUTIQUES A PROPRIETES PHARMACOCINETIQUE AMELIOREES.

Market Dynamics and Financial Trajectory for Vardenafil Hydrochloride

Last updated: February 20, 2026

What is the current market landscape for vardenafil hydrochloride?

Vardenafil hydrochloride is a phosphodiesterase type 5 (PDE5) inhibitor approved primarily for erectile dysfunction (ED). It is marketed under brand names such as Levitra and Staxyn. Globally, the ED treatment market has valued approximately $4 billion in 2022. The segment including vardenafil accounts for roughly 20% of this market, with an estimated revenue of $800 million in 2022.

Key manufacturers include Bayer, Teva Pharmaceuticals, and Sun Pharma. The generic segment's share increased from 15% in 2015 to over 50% by 2022, driven by patent expirations and regional generics proliferation.

How have regulatory and patent events influenced the market?

Bayer's patent for Levitra expired in 2018, allowing generic manufacturers to enter multiple markets. This reduced prices by an estimated 40–60%, impacting branded sales. The expiration facilitated increased accessibility and expanded the patient base, especially in emerging markets.

In the US, the final patent expiration occurred in 2020. The European patent expired in 2017, leading to a surge in generic imports. Patent cliffs across major markets significantly shifted revenue streams, transitioning from branded dominance to a generics-focused market.

What are the current pharmacological and commercial trends?

The drug's pharmacology remains stable with a half-life of 4–5 hours, allowing for flexible dosing. It competes with tadalafil (Cialis) and sildenafil (Viagra), which have similar efficacy but differ in duration and side effect profile.

Commercially, the ED market is expanding due to increasing prevalence related to aging populations and rising awareness. The global aging demographic is expected to increase ED prevalence from 10% to 30% in men aged 40–70.

Market growth is driven by increased focus on sexual health, over-the-counter availability in some regions, and newer formulations improving patient adherence. The popularity of combination therapies and the rise of telemedicine further influence demand dynamics.

What are the future revenue projections and growth drivers?

Projection estimates forecast the ED market reaching over $6.5 billion globally by 2028, with vardenafil contributing approximately 15–20% of this value. Compound annual growth rate (CAGR) calculations suggest a 5–6% growth from 2023 to 2028, primarily propelled by:

• Expansion into emerging markets (Asia-Pacific, Latin America)
• Increased acceptance of generics, reducing patient costs
• Rise in over-the-counter product availability
• Technological innovations in formulation (e.g., fast-dissolving tablets)

Regional variations could influence market share: North America is expected to be the dominant segment, but Asia-Pacific will witness the fastest growth, with a CAGR near 8%, due to higher prevalence and lower treatment access costs.

How do manufacturing and regulatory policies impact financial prospects?

Manufacturing costs for vardenafil have declined due to economies of scale and global production. Generic production costs are estimated at $0.10–$0.15 per pill, compared to branded formulations at $1.00–$2.00, creating profit margins of 85–90% for generics.

Regulation impacts are significant. Regulatory harmonization reduces approval timelines and cost, fostering quicker market entry. Countries with streamlined approval processes, such as India and Brasil, enable faster revenue realization. Conversely, stringent regulations in the US and EU can delay launches, impacting short-term revenue but fostering long-term stability.

Pricing policies vary, with government-mandated price caps in several markets influencing profit margins. For instance, India enforces prices 30–40% lower than international reference prices, reducing profit potential but increasing volume sales.

What is the competitive landscape?

Generic vardenafil dominates due to patent expiry, with leading players capturing over 60% of the accessible market:

• Teva Pharmaceuticals: Largest global producer with extensive distribution channels.
• Sun Pharma: Focused on Asian markets, rapidly expanding in Latin America.
• Mylan: Active in the US and Europe with competitive pricing.

Brand dominance persists in some regions, especially where patent protections remain valid or where consumer preference favors branded formulations. Innovation in delivery mechanisms (e.g., fast-dissolving tabs, new formulations) is limited but ongoing, primarily driven by generic manufacturers.

What are the accompanying risks?

Market risks include:

• Patent litigation or patent extensions delaying generic entry.
• Competition from new drugs or alternative therapies.
• Regulatory changes increasing approval or manufacturing costs.
• Pricing pressures due to government-mandated price reductions.

Operational risk stems from supply chain disruptions and geopolitical issues impacting manufacturing or distribution.

Key Financial Metrics and Trends Summary

Metric	2022 Data	Future Projection (2028)
Global ED Market Value	$4 billion	$6.5 billion
Vardenafil Market Share	20% of ED market	15–20% of projected market
Revenue from Vardenafil (2022)	~$800 million	$975 million–$1.3 billion
CAGR (2023–2028)	5–6%	5–6%
Generic Market Penetration	50% (2022), rising	>70% in emerging markets

Key Takeaways

• Patent expirations significantly increased generic entry, reducing prices and expanding access.
• Revenue growth predictions remain positive but are moderated by regulatory policies and pricing pressures.
• Emerging markets will drive growth, with regional variations influencing market share.
• Innovation in formulation remains limited but could alter competitive dynamics.
• Overall, the market for vardenafil hydrochloride continues to evolve with rising demand for ED treatments and increased generic availability.

FAQs

1. How does vardenafil compare to other PDE5 inhibitors? Vardenafil has a similar efficacy profile to sildenafil and tadalafil but features a quicker onset of action. Its half-life of 4–5 hours suits flexible dosing.

2. What factors influence vardenafil's pricing? Pricing is affected by patent status, regional regulation, competition, and whether the drug is branded or generic.

3. Which markets offer the highest growth potential? Emerging markets such as India, China, and Latin America present the highest growth potential due to increasing prevalence and affordability factors.

4. Are there ongoing research efforts for new formulations? Limited, primarily from generic manufacturers focusing on fast-dissolving forms or combination therapies; innovation is more incremental than breakthrough.

5. What regulations impact future market entry? Country-specific approval processes, patent laws, and price regulations influence how quickly new generic or branded formulations enter markets.

---

References

[1] MarketsandMarkets. (2022). Erectile Dysfunction Drugs Market by Product, Distribution Channel, and Region: Global Forecast to 2028.
[2] Bayer AG. (2018). Levitra Patent Expiration Announcement.
[3] Allied Market Research. (2023). Erectile Dysfunction Drugs Market Trends.
[4] IQVIA. (2022). Global Prescription Drug Sales Data.
[5] U.S. Food and Drug Administration (FDA). (2020). Approval summary for vardenafil hydrochloride.